💊
HyQvia
human normal immunoglobulin
Sindroame de imunodeficiență;Poliradiculoneuropatie;Poliradiculoneuropatie, Polineuropatie inflamatorie demielinizantă cronică
✅ Autorizat
✅
Nu există alerte active
Acest medicament nu are penurii în curs, scrisori de siguranță sau retrageri de pe piață.
La ce se utilizează
Replacement therapy in adults, children and adolescents (0-18 years) in: Primary immunodeficiency syndromes with impaired antibody production. Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of < 4 g/L. *PSAF = failure to mount at least a 2-fold rise in IgG antibody titre to pneumococcal polysaccharide and polypeptide antigen vaccines. Immunomodulatory therapy in adults, children and adolescents (0 to 18 years) in: Chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy after stabilization with IVIg.
⚠️ Siguranță a pacientului
No
Pagina oficială EMA
https://www.ema.europa.eu/en/medicines/human/EPAR/hyqvia